Drug and disease signature integration identifies synergistic combinations in glioblastoma

Drug and disease signature integration identifies synergistic combinations in glioblastoma

Inherent or acquired resistance to treatment of glioblastoma (GBM) is nearly universal. Here, the authors introduce a platform to identify synergistic drug combinations for patient-specific treatment of GBM based on gene expression signatures and small molecule perturbation-response profiles.

Bibliographic Details
Main Authors: Vasileios Stathias, Anna M. Jermakowicz, Marie E. Maloof, Michele Forlin, Winston Walters, Robert K. Suter, Michael A. Durante, Sion L. Williams, J. William Harbour, Claude-Henry Volmar, Nicholas J. Lyons, Claes Wahlestedt, Regina M. Graham, Michael E. Ivan, Ricardo J. Komotar, Jann N. Sarkaria, Aravind Subramanian, Todd R. Golub, Stephan C. Schürer, Nagi G. Ayad
Format: Article
Language:English
Published: Nature Publishing Group 2018-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-07659-z

Internet

https://doi.org/10.1038/s41467-018-07659-z

Similar Items